Table 2.
Univariate and multivariate analyses of prognostic factors for overall survival
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| P value | HR | 95% CI | P value | HR | 95% CI | |
| Age, y (≤70/>70) | .942 | 1.015 | 0.656‐1.564 | |||
| Gender (male/female) | .665 | 0.893 | 0.551‐1.516 | |||
| BMI, kg/m2 (≤22/>22) | .882 | 1.033 | 0.661‐1.597 | |||
| HBV (N/Y) | .459 | 1.252 | 0.705‐2.431 | |||
| HCV (N/Y) | .899 | 1.028 | 0.665‐1.582 | |||
| CRP, mg/dL (≤0.20/>0.20) | <.001 | 2.996 | 1.915‐4.636 | .563 | 1.256 | 0.579‐2.762 |
| Alb, g/dL (≥3.5/<3.5) | <.001 | 2.519 | 1.525‐4.017 | .353 | 2.038 | 0.432‐8.869 |
| AST, IU/L (≤35/>35) | .028 | 1.619 | 1.051‐2.501 | .871 | 1.048 | 0.592‐1.856 |
| ALT, IU/L (≤34/>34) | .592 | 1.128 | 0.721‐1.743 | |||
| Plt, ×104/mm3 (≥14/<14) | .099 | 1.437 | 0.933‐2.232 | |||
| PT, % (≥80/<80) | .838 | 0.948 | 0.552‐1.551 | |||
| T. Bil, mg/dL (≤1/>1) | .189 | 1.449 | 0.822‐2.413 | |||
| ICGR15, % (≤15/>15) | .037 | 1.584 | 1.026‐2.455 | .343 | 1.331 | 0.734‐2.412 |
| AFP, ng/mL (≤10/>10) | .022 | 1.665 | 1.074‐2.608 | .244 | 1.368 | 0.807‐2.352 |
| DCP, mAU/mL (≤100/>100) | <.001 | 2.356 | 1.525‐3.675 | .212 | 1.492 | 0.794‐2.805 |
| Child‐Pugh (A/B) | .012 | 2.378 | 1.224‐4.225 | .608 | 1.246 | 0.524‐2.835 |
| Liver damage (A/B, C) | .078 | 1.528 | 0.951‐2.395 | |||
| Tumor number (1/>1) | <.001 | 2.666 | 1.731‐4.135 | .277 | 1.403 | 0.757‐2.574 |
| Tumor size, mm (≤50/>50) | <.001 | 3.068 | 1.935‐4.775 | .042 | 2.089 | 1.024‐4.236 |
| Anatomical resection (Y/N) | .274 | 1.305 | 0.814‐2.172 | |||
| Operation time, min (≤300/>300) | .001 | 2.109 | 1.331‐3.439 | .934 | 1.026 | 0.546‐1.964 |
| Blood loss, mL (≤1000/>1000) | <.001 | 2.988 | 1.667‐5.045 | .037 | 2.211 | 1.051‐4.427 |
| LC (N/Y) | .041 | 1.631 | 1.018‐2.571 | .013 | 2.227 | 1.179‐4.278 |
| MVI (N/Y) | <.001 | 3.193 | 2.031‐4.945 | .103 | 1.625 | 0.904‐2.886 |
| Histological grade | ||||||
| Well, moderately differentiated/poorly differentiated | <.001 | 10.58 | 2.351‐186.7 | .799 | 0.404 | 0.321‐0.857 |
| IM (N/Y) | <.001 | 4.579 | 2.825‐7.234 | .127 | 1.765 | 0.847‐3.602 |
| PNI (≥40/<40) | <.001 | 2.958 | 1.915‐4.567 | .377 | 0.707 | 0.338‐1.548 |
| CAR (≤0.027/>0.027) | <.001 | 3.976 | 2.556‐6.275 | .046 | 2.171 | 1.012‐4.462 |
| GPS (0/1, 2) | <.001 | 2.982 | 1.876‐4.656 | .602 | 1.537 | 0.292‐7.658 |
| NLR (≤2.2/>2.2) | .028 | 1.629 | 1.052‐2.511 | .773 | 1.098 | 0.571‐2.062 |
| LMR (≥3.3/<3.3) | .081 | 1.541 | 0.947‐2.433 | |||
| PLR (≤106/>106) | .788 | 1.061 | 0.688‐1.648 | |||
| PI (0/1, 2) | .015 | 2.231 | 1.177‐3.901 | .361 | 0.558 | 0.137‐1.886 |
AFP, alpha‐fetoprotein; Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CAR, C‐reactive protein to albumin ratio; CRP, C‐reactive protein; DCP, des‐gamma‐carboxyprothrombin; GPS, Glasgow prognostic score; HBV, hepatitis B virus; HCV, hepatitis C virus; ICGR15, indocyanine green retention rate at 15 min; IM, intrahepatic metastasis; LC, liver cirrhosis; LMR, lymphocyte to monocyte ratio; MVI, microvascular invasion; NLR, neutrophil to lymphocyte ratio; PI, prognostic index; PLR, platelet to lymphocyte ratio; Plt, platelet count; PNI, prognostic nutritional index; PT, prothrombin time; T. Bil, total bilirubin.